Holders — by stockHoldings — by fund
Frazier Life Sciences Management, L.P.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001892134
$4.59B
disclosed book value
41
positions
19.6%
largest position share
Positions, as of 2026-06-30
top 41 of 41 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | MIRMMIRUM PHARMACEUTICALS INC | 7.7M | $899.1M | 19.6% |
| 2 | NAMSNEWAMSTERDAM PHARMA COMPANY | 18.1M | $613.0M | 13.3% |
| 3 | ERASERASCA INC | 25.0M | $457.5M | 10% |
| 4 | MBXMBX BIOSCIENCES INC | 6.7M | $367.2M | 8% |
| 5 | ARQTARCUTIS BIOTHERAPEUTICS INC | 9.9M | $258.9M | 5.6% |
| 6 | TRVITREVI THERAPEUTICS INC | 9.9M | $185.4M | 4% |
| 7 | KRYSKRYSTAL BIOTECH INC | 481,307 | $178.9M | 3.9% |
| 8 | MAZEMAZE THERAPEUTICS INC | 5.0M | $150.2M | 3.3% |
| 9 | PHATPHATHOM PHARMACEUTICALS INC | 12.5M | $135.3M | 2.9% |
| 10 | PVLAPALVELLA THERAPEUTICS INC NE | 882,400 | $134.8M | 2.9% |
| 11 | BBIOBRIDGEBIO PHARMA INC | 1.5M | $115.3M | 2.5% |
| 12 | IRONDISC MEDICINE INC | 1.4M | $99.1M | 2.2% |
| 13 | CYTKCYTOKINETICS INC | 1.2M | $98.8M | 2.2% |
| 14 | DYNDYNE THERAPEUTICS INC | 3.2M | $70.0M | 1.5% |
| 15 | ASCENDIS PHARMA A/S | 225,155 | $60.1M | 1.3% |
| 16 | SVRASAVARA INC | 9.7M | $59.9M | 1.3% |
| 17 | PBLSPARABILIS MEDICINES INC | 1.9M | $52.6M | 1.1% |
| 18 | AURAAURA BIOSCIENCES INC | 7.1M | $50.4M | 1.1% |
| 19 | ACHVACHIEVE LIFE SCIENCE INC | 7.6M | $49.7M | 1.1% |
| 20 | VORVOR BIOPHARMA INC | 2.5M | $46.8M | 1% |
| 21 | ALLOALLOGENE THERAPEUTICS INC | 22.4M | $46.7M | 1% |
| 22 | TARSTARSUS PHARMACEUTICALS INC | 728,644 | $45.9M | 1% |
| 23 | BCRXBIOCRYST PHARMACEUTICALS INC | 4.0M | $40.1M | 0.9% |
| 24 | ALKSALKERMES PLC | 700,647 | $36.7M | 0.8% |
| 25 | ACADACADIA PHARMACEUTICALS INC | 1.4M | $36.4M | 0.8% |
| 26 | ZLABZAI LAB LTD | 1.9M | $36.1M | 0.8% |
| 27 | MNKDMANNKIND CORP | 6.6M | $28.1M | 0.6% |
| 28 | DSGNDESIGN THERAPEUTICS INC | 1.8M | $26.2M | 0.6% |
| 29 | ACRSACLARIS THERAPEUTICS INC | 4.9M | $26.1M | 0.6% |
| 30 | STTKSHATTUCK LABS INC | 3.8M | $26.0M | 0.6% |
| 31 | KLRAKAILERA THERAPEUTICS INC | 1.1M | $24.2M | 0.5% |
| 32 | GLUEMONTE ROSA THERAPEUTICS INC | 1.0M | $24.2M | 0.5% |
| 33 | LXEOLEXEO THERAPEUTICS INC | 4.8M | $22.5M | 0.5% |
| 34 | RLAYRELAY THERAPEUTICS INC | 1.0M | $19.0M | 0.4% |
| 35 | EOLSEVOLUS INC | 2.6M | $18.3M | 0.4% |
| 36 | IMCRIMMUNOCORE HLDGS PLC | 484,782 | $15.4M | 0.3% |
| 37 | VALNVALNEVA SE | 2.3M | $12.0M | 0.3% |
| 38 | NAMSWNEWAMSTERDAM PHARMA COMPANY | 500,333 | $10.7M | 0.2% |
| 39 | AUTLAUTOLUS THERAPEUTICS LTD | 4.4M | $7.1M | 0.2% |
| 40 | XLOXILIO THERAPEUTICS INC | 422,505 | $4.0M | 0.1% |
| 41 | IBIOIBIO INC | 2.0M | $3.4M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.